Exact Sciences stockholders approve Abbott acquisition, clearing final hurdle in $21bn cancer diagnostics deal

Exact Sciences Corporation (NASDAQ: EXAS) has secured overwhelming stockholder approval for its acquisition by Abbott (NYSE: ABT), with more than 99 percent of votes cast supporting the transaction, effectively removing the last major internal hurdle for one of the most consequential diagnostics deals of the decade. The all-cash acquisition values Exact Sciences at approximately $21 billion and is expected to close before the end of the second quarter of 2026, subject to remaining regulatory clearances. For Abbott, the vote locks in a strategic expansion into fast-growing cancer screening and precision oncology markets at a moment when diagnostics scale and integration matter more than incremental innovation alone.

Why Abbott is betting big on Exact Sciences to build a dominant cancer diagnostics platform at scale

Abbott’s acquisition of Exact Sciences is less about adding another product line and more about establishing a vertically integrated cancer diagnostics engine that spans screening, treatment selection, and post-treatment monitoring. Exact Sciences brings a portfolio that already generates over $3.25 billion in annual revenue, anchored by colorectal cancer screening through Cologuard and treatment decision tools such as Oncotype DX, while also advancing blood-based tests for molecular residual disease and multi-cancer early detection.

For Abbott, which already operates one of the world’s largest diagnostics businesses, the deal adds a growth vertical that is structurally insulated from short-term reimbursement volatility and tied to long-term demographic trends. Cancer incidence continues to rise globally, driven by aging populations and improved detection, and diagnostics increasingly sit upstream of therapeutic decisions. By absorbing Exact Sciences, Abbott positions itself closer to the clinical decision point rather than remaining a supporting infrastructure provider.

How Exact Sciences’ 2025 financial performance strengthened its negotiating position ahead of the deal

Exact Sciences entered the transaction from a position of improving financial strength rather than distress. The company delivered $3.25 billion in revenue in 2025, representing 18 percent growth year on year, alongside a sharp turnaround in cash flow generation. Operating cash flow reached $491 million, with free cash flow of $357 million, a dramatic improvement from prior years when investment spending weighed heavily on margins.

While Exact Sciences remains loss-making on a net basis, adjusted EBITDA reached $400 million for the full year, and gross margins remained firmly above 70 percent. This profile helped justify Abbott’s willingness to pay a premium valuation, not simply for current earnings but for a business that has already crossed the hardest execution threshold from growth-at-all-costs to scalable profitability.

What the deal signals about consolidation trends in cancer screening and precision oncology diagnostics

The transaction highlights an accelerating consolidation wave across diagnostics, particularly in cancer-related testing where standalone companies often struggle to globalize distribution, regulatory engagement, and payer negotiations. Exact Sciences built deep clinical credibility and strong brands, but scaling globally requires infrastructure, manufacturing discipline, and regulatory reach that large diversified players such as Abbott can deploy more efficiently.

This acquisition also signals that blood-based screening and molecular residual disease testing are moving from speculative pipeline bets to core strategic assets. Large diagnostics companies are no longer content licensing innovation at the margins. They want ownership, integration, and data continuity across patient pathways, especially as artificial intelligence and longitudinal data become central to clinical decision-making.

How are investors pricing Abbott and Exact Sciences after shareholder approval, and what does sentiment signal ahead of closing

Market reaction to the stockholder vote has been muted, which in itself is revealing. Exact Sciences shares have effectively traded toward the $105 per share cash consideration, reflecting high confidence in deal completion and limited perceived regulatory risk. The overwhelming shareholder approval reinforces that view and reduces residual execution uncertainty.

Abbott’s shares, meanwhile, have shown stability rather than enthusiasm, suggesting investors broadly view the acquisition as strategically sound but already priced into long-term expectations. For Abbott shareholders, the key variables are integration discipline, sustained organic growth contribution, and margin protection rather than short-term earnings accretion alone. The company has framed the deal as immediately accretive to revenue growth and gross margin, but institutional investors are likely to focus on whether Exact Sciences can maintain its innovation cadence inside a much larger organization.

What happens next if regulatory approvals proceed smoothly or encounter delays

Assuming regulatory approvals are secured on schedule, Abbott will close the transaction in the second quarter of 2026 and begin integrating Exact Sciences into its diagnostics division while maintaining the Madison, Wisconsin operating base. The transition period will be critical, particularly for pipeline programs such as blood-based colorectal cancer screening developed with Freenome and emerging multi-cancer detection assets.

If regulatory review extends beyond expectations, the primary risk is not deal failure but delayed strategic momentum. In fast-moving diagnostics markets, time matters. Delays could allow competitors to narrow technology gaps or influence reimbursement frameworks ahead of Abbott’s expanded offering. That said, the lack of obvious antitrust overlap reduces the probability of structural remedies or deal disruption.

Why Abbott’s acquisition of Exact Sciences signals a structural shift in how cancer diagnostics platforms are built and scaled

At a strategic level, Abbott’s acquisition of Exact Sciences underscores how diagnostics are evolving from episodic testing businesses into longitudinal care platforms. Cancer diagnostics increasingly shape when treatment begins, how it is selected, and how recurrence is monitored. Control over that continuum offers data advantages, clinical influence, and durable revenue streams.

For Exact Sciences, the deal crystallizes value at a moment of operational maturity, allowing its technology and teams to scale globally without the capital market volatility that often constrains standalone innovators. For the broader industry, the transaction reinforces that scale, data integration, and execution discipline now matter as much as scientific novelty.

Key takeaways on what the Abbott–Exact Sciences deal means for investors and the diagnostics industry

• Exact Sciences stockholder approval removes the final internal hurdle, making a second-quarter 2026 close highly likely.

• Abbott is acquiring a scaled cancer diagnostics platform rather than a single-product growth story.

• Exact Sciences’ improving cash flow and margins strengthened its valuation leverage in negotiations.

• The deal reflects accelerating consolidation in cancer screening and precision oncology diagnostics.

• Blood-based screening and molecular residual disease testing are becoming core strategic assets.

• Abbott investors are likely to focus on integration execution rather than near-term earnings impact.

• Regulatory risk appears limited, with minimal antitrust overlap between the two companies.

• The transaction signals a broader industry shift toward longitudinal, data-driven diagnostics platforms.